Sun Pharmaceuticals to sell some low priority Ranbaxy brands - Feedback

Drug maker Sun Pharmaceuticals has put on the block a bundle of Ranbaxy brands which are low priority in its domestic market strategy or which may overlap with its own products, top industry executives said.

The country’s largest drug maker completed acquisition of Ranbaxy last year from its Japanese owner, Daiichi Sankyo, as part of a $4 billion all-stock deal. The Ranbaxy brands that Sun is looking to sell rake in about Rs 115 crore in annual sales and the company is expecting a valuation of about 2.5x or Rs 250-270 crore for them, they said.

About news

We take care of publishing the latest investment news and highlights for Feedback

Leave a Reply

Your email address will not be published. Required fields are marked *